Short Versus Long-term Levetiracetam in Brain Tumors
Recruiting
Phase 3
Interventional Study
Seizures
Brain Tumors
Antiepileptics
Levetiracetam
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 604 (estimated)
- Sponsor
- Tata Memorial Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Levetiracetam is the commonly preferred anti-seizure medicine in patients with brain tumors. This drug has reduced the risk of seizure events occurring but is associated with a risk of side effects such as increased headache, drowsiness, loss of muscle coordination, and psychological challenges in patients. In patients undergoing appropriate treatment for brain tumors and controlled of seizures in…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: • Age ≥ 18years
* History of seizure
* Histological diagnosis of primary brain tumor
* Supratentorial location of primary tumor
* Controlled on levetiracetam monotherapy for 6 months
* Index surgery within 1 year
* Karnofsky Performance Scale (KPS) ≥ 50
Exclusion Criteria:
* K…
Contacts